Hepatoprotectants, Bile acid transporter (ASBT/IBAT) inhibitor
Comment
Treatment of cholestatic liver disease
Bylvay may not be effective in PFIC type 2 patients with ABCB11 variants resulting in non-functional or complete absence of bile salt export pump protein (BSEP-3).
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A05 BILE AND LIVER THERAPY
A05A BILE THERAPY
A05AX Other drugs for bile therapy
A05AX05 Odevixibat
D11716 Odevixibat (USAN)
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Odevixibat
D11716 Odevixibat (USAN)
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03339 Odevixibat
D11716 Odevixibat
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC10
SLC10A2 (ASBT, IBAT)
D11716 Odevixibat (USAN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug transporters
D11716
Drug groups [BR:br08330]
Transporter substrate
DG01665 ABCB1 substrate
DG03339 Odevixibat